Insulet beat Q1 expectations with $569 million in revenue and raised its 2025 outlook as global Omnipod adoption drives double-digit growth.
Latest Ratings for PODD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Feb 2022 | Raymond James | Maintains | Outperform | |
| Feb 2022 | Piper Sandler | Maintains | Neutral |
